SCHEMBL1306604

SCHEMBL1306604

CCOC(=O)CCCCC=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.59
ALDH1A1 P00352 1/20 0.59
CYP3A4 P08684 1/20 0.59
ALOX15 P16050 1/20 0.59
HSD17B10 Q99714 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
CYP1A2 P05177 1/20 0.55
NR1I2 O75469 1/20 0.53
PGR P06401 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
PTGS2 P35354 1/20 0.53
PDE4D Q08499 1/20 0.53
MAPT P10636 1/20 0.52
GAA P10253 2/20 0.48
DGKA P23743 2/20 0.45
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20398941 0.98 TSHR (0.62) TSHRALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL7946850 0.98 TSHR (0.62) TSHRALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL7290192 0.98 TSHR (0.62) TSHRALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL362356 0.98 TSHR (0.62) TSHRALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL51878 0.98 TSHR (0.62) TSHRALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL1686744 0.98 TSHR (0.62) TSHRALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL89184 0.98 TSHR (0.62) TSHRALDH1A1CYP3A4ALOX15HSD17B10
SCHEMBL3964566 0.94 NR1I2 (0.59) TSHRALDH1A1CYP3A4ALOX15HSD17B10
Nonanal SCHEMBL29163124 0.93 DGKA (0.58) TSHRALDH1A1CYP3A4ALOX15HSD17B10
Hexanal SCHEMBL10412784 0.86 TSHR (0.54) TSHRALDH1A1CYP3A4ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119219493-A Preparation method of ethyl 6, 8-dichloro octoate 苏州富士莱医药股份有限公司 2024-12-31 CN claimed
CN-103613603-A Trithio-substituted adamantane derivative, and preparation method and application thereof SUZHOU QINGSHAN BIOTECHNOLOGY CO LTD 2014-03-05 CN claimed
CN-1260779-A Epsilon-caprolactam composition and by products UNION CARBIDE CHEMICALS & PROD (US) 2000-07-19 CN claimed
US-20260078215-A1 SIGMATROPIC REARRANGEMENTS OF POLYMER BACKBONES UNIV NORTH CAROLINA CHAPEL HILL (US) 2026-03-19 US disclosed
US-12503550-B2 Sigmatropic rearrangements of polymer backbones THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2025-12-23 US disclosed
US-20250002644-A1 SIGMATROPIC REARRANGEMENTS OF POLYMER BACKBONES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-01-02 US disclosed
CN-119219493-A Preparation method of ethyl 6, 8-dichloro octoate 苏州富士莱医药股份有限公司 2024-12-31 CN disclosed
CN-113747924-B Antibody-drug conjugates and uses thereof ABL生物公司 2024-05-07 CN disclosed
WO-2023086289-A1 SIGMATROPIC REARRANGEMENTS OF POLYMER BACKBONES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-05-19 WO disclosed
US-11534434-B2 Xanomeline derivatives and methods for treating neurological disorders Karuna Therapeutics, Inc. (US) 2022-12-27 US disclosed
CN-113336540-B Ceramic green sheet and coated sheet 可乐丽欧洲有限责任公司 2022-11-08 CN disclosed
US-4766237-A REACTING 5-FORMYLVALERATE WITH AMMONIA AND HYDROGEN IN ALKANOL SOLVVENT AND HYDROGENATION CATALYST BASF AKTIENGESELLSCHAFT (DE) 1988-08-23 US disclosed
US-4731445-A Preparation of epsilon-caprolactam BASF AKTIENGESELLSCHAFT (DE) 1988-03-15 US disclosed
US-4730040-A FROM A 5-FORMYL VALERATE, HYDROLYSIS, AMMONIATION, CYCLIZATION BASF AKTIENGESELLSCHAFT (DE) 1988-03-08 US disclosed
US-4730041-A Preparation of ε-caprolactams BASF AKTIENGESELLSCHAFT (DE) 1988-03-08 US disclosed
US-4709097-A CATALYTIC ISOMERIZATION WITH ACIDIC ZEOLITE BASF AKTIENGESELLSCHAFT (DE) 1987-11-24 US disclosed
EP-0230988-A2 Process for the production of esters of 6-aminocaproic acid BASF Aktiengesellschaft (DE) 1987-08-05 EP disclosed
EP-0199210-A2 Conversion of 1,3-dioxanes into 4-oxa-aldehydes BASF Aktiengesellschaft (DE) 1986-10-29 EP disclosed
US-4315032-A ANTITHROMBOGENIC AGENTS, ANTIULCER AGENTS TEITIN LIMITED (JP) 1982-02-09 US disclosed
EP-0019475-A2 Process for preparing adjacently disubstituted ketones, novel prostaglandins E1 and anti-thrombotic compositions containing them TEIJIN LIMITED (JP) 1980-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11534434-B2 Xanomeline derivatives and methods for treating neurological disorders CHRM1, RXFP3, NPY5R TSHR 164/4885ALDH1A1 3587/4885CYP3A4 1517/4885
US-20260078215-A1 SIGMATROPIC REARRANGEMENTS OF POLYMER BACKBONES SIGMAR1, TRRAP, PIK3R4 TSHR 901/4885ALDH1A1 2104/4885CYP3A4 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.